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Introduction {#sec1}
============

Glioblastoma (GBM) remains at the forefront of highly deadly cancers with little or no breakthrough in treatment paradigms or extension of survival over the past 15 years. Numerous studies have demonstrated that GBM tumor progression and maintenance is governed by cellular hierarchies, whereby quiescent or slow cycling stem-like cells appear to give rise to a more proliferative niche of progenitors capable of self-maintenance and tumor propagation ([@bib28], [@bib47]). In addition, a developmental signature and different cell states (neural precursor cells, oligoprogenitor cells) have been identified within gliomas ([@bib50]), that seem to be maintained despite the genetic heterogeneity within and across tumors ([@bib1], [@bib6], [@bib28], [@bib47]). Nonetheless, the cell type at the origin of this developmental program/hierarchy within human GBMs has not been fully elucidated.

Radial glia (RG) cells are the first neural stem cells during embryonic development. They demonstrate unique morphology, mitotic behavior, and molecular markers in the human fetus ([@bib15], [@bib17], [@bib32], [@bib37]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). The candidacy of RG as the putative cell of origin of GBMs or other brain tumors has been raised but not proven, in part due to the absence of markers that are highly restricted to RG cells ([@bib11], [@bib33], [@bib45]). Systematic characterization of RG-like cells in the adult brain will expand our understanding of the development of cortical RG cells as well as inform future investigations of the source of brain tumors.

Here, we report a series of observations of polarized mitotic cells in GBM explants and tumor dissociates that are highly typical of RG and their characteristic mitotic behavior. We systematically examine the morphology of mitotic cells and their expression of RG-specific markers. We also perform multiple timelapse video analyses that demonstrate the unique mitotic behavior associated with RG cells. RG-enriched cell dissociates form tumors *in vivo*. Single-cell RNA sequencing (scRNA-seq) analyses in human tumors identifies transcriptionally diverse cell clusters with characteristic RG and developmental gene expression. We also confirm that most RG clusters carry the main genomic aberrations of their parent tumor source. We further explore the role of inflammatory pathways, such as interleukin 1b (IL-1b) in driving dormant RG-like cells into the cell cycle.

Results {#sec2}
=======

Identification of RG-like Cells in Human GBM {#sec2.1}
--------------------------------------------

RG cells are distinguished by a unique mitotic behavior, including interkinetic nuclear migration, mitotic somal translocation (MST), and retention of a radial fiber during division, phenomena that are all distinctly uncommon in other dividing cells ([@bib54]). We evaluated sections of GBM tumors from 21 patients, for evidence of cells undergoing mitosis and exhibiting a radial fiber ([Figure 1](#fig1){ref-type="fig"}A) ([@bib20]). Mitotic cells in M phase were immunostained for phospho-histone 3 (pH3^+^) and ranged from 0.2% to 1.2% of all cells ([Table 1](#tbl1){ref-type="table"}). A total of 17.8% of pH3^+^ mitotic cells had a definitive radial fiber and were immunopositive for phospho-vimentin (pVIM), which is known to be expressed in RG fibers during cell division ([@bib23]) ([Figure 1](#fig1){ref-type="fig"}B). RG cells express a range of markers that, when coupled with the appropriate developmental context and cell morphology, are characteristic of this cell state ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Although most known RG markers have been reported to be expressed in GBMs, the significance of these findings is unclear, nor is marker expression alone sufficient to identify a cell as RG. However, the unique mitotic behavior and retention of a radial fiber during cell division are highly pathognomonic to RG, so we based our approach on the co-existence of the division phenotype with typical RG markers. Therefore, we evaluated the same set of tumors for mitotic pVIM^+^ cells with a process, and co-expression of a panel of RG markers (SOX2 and FABP7, or BLBP, GLAST, PAX6, and HOPX), including the human-specific gene ARHGAP11B, as well as two human adult neural stem cell markers (P75 and GFAPδ) ([@bib49]). Most of the cells (60%--100%) were found to express one or more of these markers in addition to pVIM ([Figures 1](#fig1){ref-type="fig"}C, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D).Figure 1RG-like Cells in Human Adult GBMs(A) Representative confocal images of GBM sections. Cells in M phase are labeled with phospho-histone 3 (pH3) and their radial fiber-like processes are detected with pVIM.(B) Percentage of pVIM+ and pH3+ cells in human GBMs (n = 21 tumors).(C) Quantification of co-expression of pVim with an array of RG markers, by immunochemistry (IHC).(D) Schematic flow of the development of 3D explants from patient GBM samples. IHC demonstrates the expression of pH3 and pVim during cell division; arrows points to mitotic cells with or without process (labeled RG-like or non-RG-like).(E) Co-expression of RG-like markers in pVim+ cells in explants.Scale bars, 10 and 5 μm (A), 20 and 10 μm (D and E).Table 1Quantification of pVim and pH3 Cells in 21 Tumor Tissue SamplesPatientpVIMpH3DAPIpVIM/pH3%Mitotic Cells (pH3/DAPI)GBM1571,40750.5GBM2691,37260.66GBM310141,514100.93GBM4331,04730.29GBM518171,395171.22GBM616162,715160.59GBM7431,35530.22GBM810102,038100.49GBM9221,11120.18GBM105451130.78GBM113282420.24GBM12241,28320.31GBM135653851.12GBM14231,08920.28GBM154463240.63GBM169997890.92GBM1717171,268171.34GBM187765871.06GBM1914141,756140.8GBM206674660.8GBM2121211,693211.24

To better visualize cell morphology we performed 3D organotypic tumor cultures. These explants consist of fresh tumor tissue dissected into 1- to 2-mm pieces that are embedded in Matrigel and maintained in growth factor (GF)-free media ([Figure 1](#fig1){ref-type="fig"}D) ([@bib41]). We analyzed whole mounts of 3D cultures obtained from five different patient tumors ([Table 2](#tbl2){ref-type="table"}). We found that 27% (122/459) of pH3^+^ mitotic cells maintained a radial fiber-like process and are thus RG-like, while the remaining 73% had no fiber and exhibited a classic rounded up cytoplasm during division ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}B). These mitotic RG-like cells coexpressed RG markers BLBP, PAX6, SOX2, ARHGAP11B, and GLAST ([Figure 1](#fig1){ref-type="fig"}E). Interestingly, we observed a specific polarized orientation of the processes of RG-like cells within the explants ([Figure S1](#mmc1){ref-type="supplementary-material"}E). In more than 90% of the cells, the short processes always faced the center of an explant and the long processes extended radially away from the center of the explant. The remaining 10% of RG-like cells (pVIM^+^/pH3^+^ and maintaining a process) had curved, horizontal, or apical (long process facing toward the center) orientations.Table 2Tumor Samples Used for Examination of RG-like Cells in ExplantsTumorpVIMpH3pVIM/pH3 Cells with ProcessGBM2210911039GBM23808127GBM24545514GBM2511111222GBM2610010120

Unique RG Mitotic Behaviors {#sec2.2}
---------------------------

The human subventricular zone includes a dense outer zone that consists of outer RG (oRG) cells ([@bib19]). They exhibit a well-described pattern of cell division, MST, a characteristic migratory behavior, in which the soma rapidly translocates toward the cortical plate immediately prior to cytokinesis. Human oRG cells self-renew mainly by horizontal asymmetric division ([@bib27]), whereby one daughter cell retains the basal fiber. Inheritance of the basal fiber has been hypothesized to be important for maintenance of stem cell identity. We asked whether these phenomena could be identified in the RG-like cells within tumors, and whether they were cell intrinsic or dependent on the tumor microenvironment. Therefore, we performed extensive timelapse microscopy on tumor cell cultures and multiple explants (n = 7 tumors). We observed four major mitotic patterns. In addition to MST, we observed interkinetic nuclear migration, a phenomenon observed in ventricular RG, as well as two types of stationary cell division ([Figures 2](#fig2){ref-type="fig"}A--2C; [Video S1](#mmc7){ref-type="supplementary-material"}). Most cells maintaining a radial fiber-like process exhibited stationary division with process ([Video S2](#mmc8){ref-type="supplementary-material"}). Half of the mitotic cells retracted their protrusion and divided in place, as is commonly observed in most cell types (stationary division without process). Out of 256 observed divisions, 57% of dividing cells maintained their processes during mitosis and 16.3% of the mitotic cells with radial fiber-like processes demonstrated unique RG mitotic behavior. Interestingly, we also observed tumor cells moving along the processes of RG-like cells, as has been described for neuronal migration during development ([Figure S2](#mmc1){ref-type="supplementary-material"}A; [Video S3](#mmc9){ref-type="supplementary-material"}). Furthermore, some daughter cells went through MST along a similar division trajectory as their mother cells ([Figure S2](#mmc1){ref-type="supplementary-material"}B; [Video S4](#mmc10){ref-type="supplementary-material"}). Having observed these behaviors both in explants and dissociated cells albeit at a lower frequency, we reasoned that cell-intrinsic mechanisms that are independent of tumor microenvironment are responsible for the establishment of cleavage angles and the control of mitotic behavior in tumor RG-like cells. To correlate this mitotic behavior with specific RG molecular markers, we performed timelapse imaging of cultures of freshly sorted CD133^+^ tumor cells, identified cells undergoing MST, and then fixed the samples and examined the expression of oRG-specific markers. We observed that daughter cells after MST express pVIM/HOPX/BLBP or CRYAB/HOPX/SOX2 ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C; [Video S5](#mmc11){ref-type="supplementary-material"}); cells undergoing stationary division without a process were negative for the same markers ([Figures 2](#fig2){ref-type="fig"}D and 2E).Figure 2Human RG-like Mitotic Behavior and Division PlanesFrames from timelapse microscopy show four major types of mitotic behavior in explants.(A) Human oRG-specific MST pattern: the cell body moves along the process and accomplishes a fast movement over a significant distance before cytokinesis (dotted white lines); ventricular RG-specific interkinetic nuclear migration: cells move along the process up and down during mitosis; arrow heads point to the nucleus and the stars to the daughter cells; stationary divisions occur without significant movement (dotted line).(B and C) Real-time images show a cell undergoing MST (arrowheads) in (B). Immediate fixation shows the same two daughter cells visible in the last frame (200) and identified with stars. Both cells are immunopositive for pH3, pVIM, and BLBP while only one daughter cell retains the elongated fiber process as shown in (C). Dotted contour around the RG-like fiber in (B).(D and E) Similar approach identifies a cell without process undergoing stationary division in (D) and negative for RG markers in (E).(F) RG cells in explants undergoing division along a horizontal plane. Schematic figures define the cleavage planes (top panel).(G and H) Immunohistochemistry on brains injected with GBM cells expressing CD133 or CD133/GLAST (G). Strong tropism toward the subventricular zone (SVZ) in the CD133/GLAST group, quantified as percent of human cells in V (ventricle), SVZ, and Cx (cortex) in (H).(I and J) Immunohistochemistry of tumor cells in the SVZ region shows RG-like morphology in GFP-labeled human cells lining the SVZ, and expressing SOX2 in (I) and GLAST/BLBP in (J).Scale bars, 10 μm (A), 20 μm (C, D, E, F, and I), 100 μm (G), 20 and 10 μm (J). DP, double-positive or CD133 ^+^/GLAST^+^. Time in (A)--(D) in minutes.

Video S1. Mitotic Somal TranslocationCells with mitotic somal translocation (oRG-like) are highlighted in yellow and cell bodies are tracked by yellow arrow. The cells dividing in place with or without process are indicated in green and blue separately.

Video S2. Real-Time Imaging Shows a Cell Maintaining Its Process and Dividing in PlaceDaughter cell regrows the process after division.

Video S3. Interkinetic Nuclear Movement in Dividing Tumor CellsCell undergoing interkinetic nuclear movement is highlighted in yellow. The cell body moves along the long process toward the end of the short process then back toward the end of the long process for mitosis. The yellow arrow tracks the cell body movement. Daughter cells inherit one process and regrow another one after division. In the same field, other cells retract the cytosol/process and divide in a stationary manner (blue).

Video S4. Mitotic Somal Translocation in Three Consecutive DivisionsoRG-like mother and daughter cells divide via MST, a behavior suggestive of self-renewal.

Video S5. The Long Process of RG-like Cell Guides the Migration of Another Cell

Human oRG cells are self-renewed by horizontal division. Therefore, we characterized cell division in both organotypic (explants) and dissociated low-passage cell cultures. We found that 68% of RG-like mitotic cells displayed a horizontal cleavage plane in explant cultures, while 85% did so in dissociated cultures of freshly sorted CD133^+^ cells from surgical GBM specimens ([Figures 2](#fig2){ref-type="fig"}F, [S2](#mmc1){ref-type="supplementary-material"}D, and S2E). The remaining RG-like cells exhibited a vertical or oblique plane of cleavage. Dissociated cells undergoing vertical divisions spent a significantly longer time in cytokinesis compared with cells dividing horizontally (160 and 60 min, respectively) ([Figure S2](#mmc1){ref-type="supplementary-material"}F).

RG-like Tumor Cells Form Tumors *In Vivo* {#sec2.3}
-----------------------------------------

In view of the heterogeneous nature and low prevalence of RG-like cells in GBMs, as well as the absence of pathognomonic surface markers, we attempted to empirically enrich for RG-like cells using GLAST expression, consistent with the studies using CD133/GLAST to isolate human fetal RG cells or mouse adult neural stem cells (NSCs) ([@bib22]) and with our data on markers coupled with MST behavior. Bulk qRT-PCR for an RG gene panel performed on GLAST^+^ cells sorted from two different GBMs and demonstrated that GLAST^+^ cells exhibited higher expression levels for RG markers compared with GLAST^−^ cells, indicating that GLAST may represent a promising additional membrane marker for further studies ([Figure S3](#mmc1){ref-type="supplementary-material"}A). We analyzed GLAST expression by fluorescence-activated cell sorting (FACS) in nine tumors and found it in an average of 7.37% ± 0.05% ([Table 3](#tbl3){ref-type="table"}). We also confirmed that GLAST-expressing cells are capable of propagating a tumor *in vivo*. We dissociated freshly obtained GBMs and sorted for CD133 and/or GLAST subsets. We injected four cell groups (CD133^+^, GLAST^+^, CD133^+^GLAST^+^, and double-negative) into the striatum of NOD/SCID gamma mice. All but the double-negative group developed brain tumors. Interestingly, the CD133^+^GLAST^+^ cells showed a significant tropism toward the subventricular zone when compared with the other groups ([Figures 2](#fig2){ref-type="fig"}G and 2H) where they exhibited typical RG-like morphology ([Figure 2](#fig2){ref-type="fig"}I) and coexpressed GLAST and BLBP ([Figure 2](#fig2){ref-type="fig"}J).Table 3GLAST Expression by FACS AnalysisTumor%GLAST+GBM3911.40GBM402.90GBM290.30GBM225.50GBM2313.90GBM2417.10GBM256GBM262.10GBM307.10

Characterization of RG-like Tumor Cells via scRNA-Seq {#sec2.4}
-----------------------------------------------------

At present, RG-specific clusters have not been reported in scRNA-seq studies. We performed scRNA-seq on sorted CD133/GLAST-expressing tumor cells from three freshly procured human GBMs (GBM 27, GBM 28, and GBM 29, profiled in [Table S1](#mmc1){ref-type="supplementary-material"}; available profiles of all tumors used in this article are listed in [Table S2](#mmc4){ref-type="supplementary-material"}) for a total of 13,251 viable cells that passed quality controls; CD45+ cells were excluded and 12,490 cells were used in the analysis. We analyzed each tumor individually. To overcome the issue of missing transcripts, typical of scRNA-seq, and to de-noise the data we used MAGIC (Markov affinity-based Graph Imputation of Cells) ([@bib48]). We performed unsupervised clustering of the cells using PhenoGraph, a well-established method that has previously been used to robustly infer clusters or cellular subtypes from single-cell data ([@bib40], [@bib53]). Cluster numbers and sizes are listed in [Table S3](#mmc5){ref-type="supplementary-material"}.

To identify RG-like cells, we used RG gene sets ([Table S4](#mmc6){ref-type="supplementary-material"}) that were identified in studies of dissected human developing brains ([@bib37]). We then used Earth Movers\' Distance (EMD) ([@bib30]) to characterize and annotate clusters. For this, we computed EMD between genes belonging to the RG gene sets in each cluster compared with the rest. We detected six to seven RG-like clusters per tumor independently, confirming the presence of RG-like cells in all specimens ([Figure 3](#fig3){ref-type="fig"}A). We used the same approach to segregate the cycling and non-cycling cell compartments ([Figure 3](#fig3){ref-type="fig"}B). Cell-cycle gene sets were obtained from Kyoto Encyclopedia of Genes and Genomes pathway and gene ontology analysis (see [Experimental Procedures](#sec4){ref-type="sec"}).Figure 3Single-Cell Transcriptional Analysis of GBM Cells Reveals a Population of RG-like Cells(A) EMD heatmaps to identify RG-like clusters in the analyses of individual patient data.(B) RG-like cells in individual patient data are segregated into non-cycling (orange) and cycling (green) based on EMD scores for cell-cycle gene sets (top panel). Diffusion maps on raw data using all genes demonstrate the distribution of RG-like cells in individual patients. Each dot represents a cell and each axis represents a diffusion component. The cells are color coded based on the clusters they belong to.(C) Expression distribution of RG markers (HOPX, IL6ST, LIFR, and BLBP) are shown for individual tumors. Orange and blue lines represent the expression of a specific gene in the indicated cluster and its expression in the rest of the data, respectively.(D) Immuno-FISH on sections from four patients show colocalization of pVim with the *EGFR* probe.(E) CNV analysis of chromosome 7 in RG- and non-RG-like cells (n = minimum of 50 nuclei per tumor). Scale bar, 8 μm.

We then sought to study any possible relationship between cycling and non-cycling RG-like cells in each tumor. For this, we performed a diffusion component ([@bib38]) analysis to get an accurate representation of the underlying structure of the data. Scatterplot of RG-like cells in individual patients along the diffusion components showed that the cycling and non-cycling cells were segregated along the data manifold with multiple intermediate states seemingly connecting them ([Figure 3](#fig3){ref-type="fig"}B). These data are highly compatible with recent literature demonstrating that NSC lineage exist on a continuum through the processes of activation and differentiation, including the presence of molecularly distinct rare intermediate stages ([@bib13]). Analysis of select individual genes demonstrated that the leukemia inhibitory factor (LIF) receptor and its coreceptor IL6ST demonstrate a trend of downregulated expression in cycling RG-like cells when compared with those in non-cycling cells, unlike HOPX and FABP, which were more heterogeneously expressed ([Figure 3](#fig3){ref-type="fig"}C). This expression pattern suggested that LIFR may be one of the membrane markers for non-cycling RG-like cells.

Genomic Aberrations in Radial Glia-like Tumor Cells {#sec2.5}
---------------------------------------------------

We analyzed copy number variation (CNV) in the scRNA-seq data as a means of confirming the neoplastic nature of the RG-like cells in individual GBMs. Using CD45^+^ immune cells as a normal cell control, CNV profiles revealed chromosomal aberrations with loss of chromosome 10 in all 3 patients, as is often reported in GBM, as well as amplifications of chromosome 7 in two tumors, as confirmed by tumor sequencing ([Figure S3](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc1){ref-type="supplementary-material"}). One of the patients (GBM27) also exhibited loss of chromosome 15 ([Figure S3](#mmc1){ref-type="supplementary-material"}B). The loss of a chromosome was reflected in the scRNA-seq data and was subsequently validated on matched tumor specimens using DNA-fluorescence *in situ* hybridization (FISH) ([Figure S3](#mmc1){ref-type="supplementary-material"}C). We also carried out immuno-FISH assays for pVIM and an *EGFR* probe to further confirm that RG-like cells in GBM are indeed of tumor origin ([Figure 3](#fig3){ref-type="fig"}D). We further analyzed the extent of chromosomal aberration in RG clusters of each individual tumor and noted interesting variations. We found that non-cycling RG-like cells maintained a more intact chromosome 15 compared with cycling RG-like cells in GBM27 ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Interestingly, C18 in GBM28 (a non-cycling cluster originating from the younger 31-year-old patient) exhibits a near normal copy number of chromosomes 10 and 7 in the setting of chromosome 7 amplification and chromosome 10 loss exhibited by the remaining matched tumor cells ([Figure S3](#mmc1){ref-type="supplementary-material"}E). In both GBM28 and GBM29, RG-like cells had significantly less focal chromosome 7 amplification compared with non-RG-like cells ([Figure 3](#fig3){ref-type="fig"}E). These findings largely confirm the neoplastic nature of the RG-like cells, and raise the possibility of retention of normal cells with an RG-like transcriptomal profile within the adult brain or brain tumor, but they should be interpreted cautiously in view of the small sample size.

Non-cycling Radial Glia-like Cells Are Activated by Inflammation Signaling {#sec2.6}
--------------------------------------------------------------------------

The activation of quiescent NSCs has been linked to the transcriptional upregulation of factors critical for protein synthesis machinery, such as multiple ribosomal genes, and oxidative phosphorylation ([@bib31]). Several authors have also described morphological ([@bib8]) and transcriptional features associated with dormancy (a deep quiescence state), such as absence of cell cycling, low protein synthesis, and *EGFR* gene expression ([@bib42]). These factors are activated upon transition out of dormancy and progression along cell differentiation stages ([@bib5], [@bib25]). *In vitro* assays showed significant differences at baseline between freshly sorted RG and non-RG-like cells. While non-RG cells maintained protein synthesis (using the O-propargyl-puromycin incorporation or Op-puro assay) in epidermal GF (EGF)- or fibroblast GF-enriched and GF-free media, the RG cells had undetectable global protein synthesis at baseline and it was upregulated in the GF media ([Figure 4](#fig4){ref-type="fig"}A). Treatment with IL-1b, but not with bone morphogenetic protein (BMP), LIF, or EGF, upregulated EGFR, the dormant cell marker ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Based on the observation that LIFR^+^ cells are significantly enriched in IL-1R1^+^ cells ([Figure S4](#mmc1){ref-type="supplementary-material"}B), we sorted out GLAST^+^LIFR^+^ cells to test the role of IL-1 in driving dormant RG-like cells into the cell cycle. Treatment with IL-1b significantly upregulated protein synthesis ([Figure 4](#fig4){ref-type="fig"}B) and the mRNA and protein expression of *EGFR* ([Figure 4](#fig4){ref-type="fig"}C) in RG-like but not non-RG cells. Concomitantly, the expression of the cell-cycle marker Ki67 was also increased, indicating entry into the cell cycle ([Figure 4](#fig4){ref-type="fig"}D). Enhancement of protein synthesis occurred within 10 min of exposure to IL-1b ([Figure S4](#mmc1){ref-type="supplementary-material"}C). These data suggest that the interleukin inflammation signaling pathway can activate the dormant tumor RG-like cells and trigger their entry into the cell cycle *in vitro*.Figure 4Inflammation Regulates Cell-Cycle States of RG-like Cells(A) Immunohistochemistry for GLAST and protein synthesis (OP-puro) in growth factor (GF) and GF-free conditions.(B) IL-1b treatment activates RG-like cells coexpressing GLAST^+^LIFR^+^ by stimulating protein synthesis (OP-puro) and the expression of EGFR. Quantification of general protein synthesis and expression of EGFR protein in the indicated cell groups (right panel), p = 0.0008 (OP-puro), p = 0.019 (EGFR).(C) RNA-FISH showing that IL-1b activates the transcription of *EGFR* in RG-like cells and while *CRYAB* expression is maintained.(D) Treatment with IL-1b for 72 h significantly increases Ki67 in GLAST^+^LIFR^+^ cells, signifying entry into the cell cycle (n = 6, triplicate from two patients). Scale bars, 20 μm (A, B, and D), 50 μm (C).(E and F) IHC for GLAST (E) in a set of matching primary (left) and recurrent (right) tumors quantified in (F). n = 4 pairs, Mann-Whitney.

Interleukin IL-1b is a potent cytokine that is a major component of the microglia secretome; its levels are increased in GBMs and it is a component of the pro-inflammatory cascade elicited by radiation. We then asked if GLAST-expressing cells might be more abundant at the time of tumor recurrence. We identified four patients with available matching tumor tissues from initial diagnosis and recurrence. GLAST expression by immunohistochemistry was heterogeneous but significantly and consistently more increased in the recurrent tissues ([Figures 4](#fig4){ref-type="fig"}E and 4F). Analysis of large datasets from cBioPortal also confirm a negative correlation between *GLAST* expression levels and extent of survival, as well as more increased levels in patients who have recurrence within 6 months compared with those remaining disease free ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E).

Discussion {#sec3}
==========

RG cells are the earliest NSCs in the neuroectodermal lineage. In higher mammals, oRG cells contribute to the evolutionary expansion and folding of the neocortex, and to the increased diversity of neural progenitor populations ([@bib43]). It is not clear if RG cells could persist into adulthood. In this study, we demonstrate the presence of cells with RG features within adult GBMs. Initial observations showed rare but consistent RG-like morphology during mitosis as demonstrated by pH3 and pVim immunohistochemistry on a set of 21 GBM specimens. Using extensive timelapse microscopy, we demonstrate and quantify RG-specific mitotic behavior, including MST and interkinetic nuclear migration in GBM cells in 3D cultures and early passage cells. We also demonstrate that RG-like tumor cells are capable of self renewal as they give rise to generations of daughter cells with identical mitotic behavior. Combined timelapse video and immunofluorescence demonstrate co-labeling of the cells with RG-typical markers, such as GLAST, HOPX, and BLBP. Sorting for GLAST-expressing cells resulted in enrichment for RG genes, so we sorted GBM cells from three different tumors and performed scRNA-seq analysis. Unbiased clustering showed multiple cell groups within each specimen, and six to seven clusters per tumor that are enriched for fetal RG genes. Further analyses identify quiescent and active states within the RG clusters that are highly similar to those described in adult stem cell niches.

Careful analysis of the scRNA-seq data did not reveal a single pathognomonic marker or a combination thereof that would allow the prospective isolation of definitive RG-like cells from GBMs. We therefore used marker combinations to enrich for these cells. *In vitro* assays demonstrate a role for IL-1b in the activation of potentially dormant RG-like cells, associated with the upregulation of protein synthesis and downregulation of EGFR. Inflammation plays a critical role in tumor progression ([@bib10]). IL-1b is a major mediator of inflammation in the brain and is expressed in the microglia secretome ([@bib34]). Our findings could suggest a role for inflammation or microglial activation in accelerating the proliferation of RG-like tumor cells. All GBMs receive radiation and chemotherapy, known to be associated with increased inflammation. We validated a potential role for GLAST protein expression in tumor recurrence, by demonstrating significant increase in its expression in matching sets of initial and recurrent tumors; in large datasets, we also found *GLAST* expression levels to be increased in recurrent GBMs and to correlate with poorer overall survival and early disease progression.

Estimated copy-number analyses confirmed the presence of genomic aberrations within RG clusters, matching those found in the tumors of origin. Interestingly, we found that major aberrations, such as large chromosomal losses or gains were most prevalent in the non-RG clusters, with the non-cycling RG compartment comprising genome copy numbers that are closest to the normal diploid genome. These data raise the possibility of maintenance of normal RG cells in the human adult brain.

Taken together, these data support current findings of conserved developmental hierarchies within GBM, and identify RG cells as the putative stem cells underlying this program. The paucity of the cells and the permissive expression of commonly recognized RG markers, as well as the difficulty in maintaining or expanding the cells in their RG state *in vitro*, pose a challenge for more advanced studies. The data also support the existence of conserved molecular dynamics of activation of quiescent NSCs within GBM, that mimic those identified in the neural stem cell niche of the developing brain. We hypothesize that RG-like tumor cells could represent the cells of origin or the cancer stem cells residing at the top of the tumor cell hierarchy, capable of transitioning into an active state and fueling tumor growth with a diversity of neural progenitors, although further data would be required to functionally validate this concept. Enhanced understanding of these cells and of the molecular factors that trigger their activation will lead to novel therapeutic targeting strategies. Hence, the role of interleukin in tumor maintenance should be further investigated. The data also hint at the possibility of persistence of normal RG cells into adulthood, when they might be vulnerable to tumorigenic transformation.

Experimental Procedures {#sec4}
=======================

Dissociation and FACS Sorting of Human GBM Specimens {#sec4.1}
----------------------------------------------------

Surgical specimens were collected from the surgical suite at Memorial Sloan Kettering Cancer Center, following diagnostic confirmation by a neuropathologist. Tissues were obtained in accordance with international review board guidelines. Single-cell suspensions were obtained based on our previously published methods ([@bib52]) with minor modification to reduce processing time. In brief, tumor tissue was cut into 2-mm^2^ pieces and enzymatically digested with Liberase for 5--10 min at 37°C. The suspension was passed through a cell strainer. Red blood cells (RBCs) were depleted with RBC lysis buffer (eBioscience, cat no. 00-4333-57) for 3 min at 37°C. The cell suspension was then blocked with FcR (Miltenyi Biotec, cat. no. 130-059-901) for 5 min and incubated with appropriate conjugated antibodies for 10 min at room temperature. The cells were pelleted by centrifugation at 219 × *g* for 3 min. The approach of sorting fixed single cells was adopted from a published protocol ([@bib46]). In brief, RBCs and CD45 hemopoietic cells in single-cell suspensions were removed by RBC lysis buffer and CD45 MACS beads with LS columns (Miltenyi Biotec, cat no. 130-045-801). Cells were then fixed with 4% paraformaldehyde (Electron Microscopy Sciences) and sorted for cell size and DAPI signal. A few hundred cells from the gate of singlet and DAPI selection were sorted to confirm single cells and absence of debris, before sorting single cells using a 120-μm nozzle for specific antibodies into an 8-strip PCR tube (Fisher) containing 5 μL of PKD buffer (QIAGEN) with 1:16 proteinase K solution (QIAGEN). Antibodies used in sorting included: APC-conjugated CD133 (AC141 and AC133, 1:500 each, Miltenyi Biotech, 130-090-854 and 130-090-826); PE-conjugated GLAST (1:1,000, Miltenyi Biotec, 130-098-804); APC-GLAST (1:800, Miltenyi Biotec, 130-098-803); PE-conjugated PAX6 (1:400, BD Bioscience, 561552); PE-conjugated LIFR (1:500, R&D Systems, FAB249P). For live cell sorting, cells positive for markers of interest but negative for DAPI were sorted on the Aria sorter and collected in N2 medium. Negative controls consisted of unstained sample and IgG control. Pilot experiments verified gating by immunostaining cells after sorting.

*In Vivo* Studies {#sec4.2}
-----------------

Adult female NOD/SCID or male NOD/SCID gamma mice (Jackson Laboratory, Bar Harbor, Maine) were anesthetized with ketamine/xylazine (Hospira, Lake Forest, Illinois/Inc/Ben Venue Laboratories) and placed in a stereotaxic frame (Stoelting Company, Wood Dale, Illinois). Freshly sorted cells were injected into the right striatum immediately after sorting ([@bib52]). Animals received 10,000 cells each from 4 groups of CD133^+^, GLAST^+^, CD133^+^/GLAST^+^, or CD133^--^/GLAST^−^ cells. Animals were sacrificed upon exhibiting symptoms (n = 10). Animals were housed and cared for in accordance with the NIH guidelines for animal welfare, and all animal experiments were performed in accordance with protocols approved by our Institutional Animal Care and Use Committee.

Cell and Explant Cultures {#sec4.3}
-------------------------

Freshly sorted CD133^+^ cells were cultured in adherent culture conditions on plates coated with poly-L-ornithine hydrobromide (15 μg/mL, Sigma), mouse laminin I (4 μg/mL, R&D Systems), and fibronectin (2 μg/mL, Fisher Scientific). The adherent cells were maintained in serum-free neurobasal medium supplemented with N2, 2 mM L-glutamine, 20 ng/mL recombinant human EGF, and 10 ng/mL recombinant human fibroblast GF 2 (all from Invitrogen). About 2 mm tumor tissue explants were cultured in GF-reduced Matrigel (BD 354230) in N2 medium without supplementing any GFs. Real-time imaging was carried out 4--6 days after *in vitro* culture.

For activation assays, indicated cell types were cultured after sorting in the adherent culture conditions as above in GF-free N2 medium for 2 days. Cells were stimulated with 10 ng/mL final concentration of human LIF (Sigma), or 10 ng/mL final concentration of human BMP7 (R&D Systems), or 20 ng/mL final concentration of human EGF (R&D Systems), or 25 ng/mL final concentration of human IL-1b (R&D Systems) for the indicated time.

scRNA-Seq {#sec4.4}
---------

Sorted tumor cells from human GBM specimens were washed once and resuspended in PBS containing 0.05% BSA. A dose of 21 μL of a cellular suspension at 500 cells/μL with 95% viability was loaded onto the 10X Genomics Chromium platform to generate barcoded single-cell Gel Bead-In-Emulsions. scRNA-seq libraries were prepared according to 10X Genomics specifications. The Sequence Quality Control ([@bib3]) package was used to process raw scRNA-seq reads to a transcript count matrix, including de-multiplexing, alignment, barcode and UMI error correction, and generation of a digital expression matrix. Alignment was performed to the hg38 annotation restricted to transcribed, polyadenylated RNA of length \>200 nucleotides to increase mapping specificity. Viable single cells were identified based on total mRNA abundance, number of unique transcripts, and mitochondria fraction. A total of 12,367 cells from 3 patients (GBM 27, 4,570; GBM 28, 4,341; and GBM 29, 3,456 cells) with a median library size of 6,152 molecules per cell were used for downstream analysis. MAGIC and PhenoGraph were used to robustly de-noise and impute scRNA-seq data, and to perform clustering, respectively. More details in the [Supplemental Methods](#mmc1){ref-type="supplementary-material"} section.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Immunostaining and RNA-FISH Analyses {#sec4.5.1}

A t test was used to determine the significance of the observations. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 are used in study. Mean and error bars with standard deviation.

### CNV Analysis {#sec4.5.2}

Chromosomal CNVs were analyzed using scRNA-seq data as described previously ([@bib35]). In brief, all genes were sorted by their genomic locations and chromosomal copy number of each gene in each cell was estimated by moving average of the relative normalized expression of the neighboring 101 genes. CD45^+^ immune cells in our scRNA-seq data were used as normal cell control. To estimate the copy number of each chromosome in each cell, median expression value of all genes located in the chromosome was normalized by subtracting the median and dividing by the standard deviation averaged of all CD45^+^ immune cells. The p values were calculated using the Wilcoxon rank-sum test.

### GLAST Expression Analysis in cBioPortal Dataset {#sec4.5.3}

A glioblastoma multiforme (TCGA, Provisional) dataset from cBioPortal ([@bib16]) was used for GLAST gene expression and patient survival analysis. A total of 528 patients with both clinical and gene expression data (mRNA expression *Z* scores \[U133 microarray only\] from cBioPortal Glioblastoma Multiforme \[TCGA, Provisional\]) were used for the analysis. To analyze the relationship between GLAST gene expression and patient survival, we first grouped the patients by GLAST mRNA expression *Z* score. The GLAST mRNA *Z* score distribution ranged from −4.5282 to 1.373 and the median was 0.2089. The 25% percentile was −0.4469 and the 75% percentile was 0.5707. We set up *Z* score = ±0.5 as the threshold to group the patient as GLAST high and low expression. The group with a GLAST *Z* score more than 0.5 had 143 patients and the group with a GLAST *Z* score less than −0.5 group had 82 patients. The overall survival in months and survival status data from those patients were used for Kaplan--Meier survival analysis using Prism 8.

Among the 528 samples, 366 samples were newly diagnosed GBM; among those patients, 152 recurred within 6 months and 23 remained disease free. We compared *GLAST* expression between the two groups, using a t test. PFS6 or progression-free survival at 6 months is an appropriate time point to represent disease status after recurrence, as is commonly used in clinical trials. We performed an unpaired t test to analyze the difference in GLAST expression between the two groups, and the p value was 0.04, which means that they have a statistical difference.

### Mutation Profiles of Tumors {#sec4.5.4}

Tumors used for scRNA-seq underwent targeted sequencing by MSK-IMPACT, a hybridization capture-based next-generation sequencing assay for targeted deep sequencing of a selected cancer gene set. Full method detailed in [@bib7].
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